Seattle Genetics ranks up as a well-established and successful biotechnology company globally. The company came into inception in 1998 with an objective of creating and commercializing empowered and innovative monoclonal antibody-based therapies that target the treatment of cancer.
Since its inception, it has managed to position itself as a premier developer of antibody-drug conjugates. ADCs utilize a technology that harnesses the potential of monoclonal antibodies in delivering killing agents to cancer cells directly. The ADCs spare non-targeted cells while reducing the numerous toxic effects associated with traditional chemotherapy.
Seattle Genetics prides itself on the success of its ADCETRIS product. ADCETRIS has entered various markets across the globe including the European Union, the United States, Canada and Japan. Currently, the company is making various endeavors of assessing another antibody-drug conjugate technology using pyrrolobenzodiazepine (PMB) dimer, a highly effective cytotoxic agent.
The company boasts of multiple partnerships, which comprise of an agreement with Genentech for SGN-40 priced over $860 million. The multiple agreements also consist of ADC collaborations with other companies such as Medlmmune, Progenics, Bayer and CuraGen. Since 2011, the ADC agreements have generated over b$65 million for Seattle Genetics.
Clay Siegall, popularly known as Dr. Siegall, is acknowledged for co-founding the Seattle Genetics, a premier biotechnology company, in 1998. Apart from being the co-founder of Seattle Genetics, he serves as its Chief Executive Officer, President as well as Chairperson of the Board of Directors. Clay has significantly aided Seattle Genetics in the creation of a diverse pipeline comprising of antibody-based cancer therapies. ADCETRIS (brentuximab vedotin) serves as one of the company’s main therapies, especially after gaining approval from the US Food and Drug Administration in 2011.
Siegall has also proven to be highly qualified in attracting financiers, as he has assisted Seattle Genetics in securing over $675 million via both private and public funding. His academic qualifications is characterized by a B.S degree in Zoology from the popular University of Maryland and a Genetics Ph.D. from the George Washington University. With such an impressive academic record of accomplishment, he has served numerous entities such as the National Institutes of Health, National Cancer Institute, and the Bristol-Myers Squibb Pharmaceutical Research Institute.
Velma Gutierrez September 29, 2016
Posted In: Cancer Research